Viatris Stock Forecast for 2023 - 2025 - 2030
Updated on 05/31/2023
Viatris Stock Forecast and Price Target
The average price target for Viatris's stock of $13.50 recently provided by eight leading analysts would represent a 47.06% upside from its last closing price if reached. This potential increase is based on a high estimate of $18.00 and a low estimate of $10.00. You may be interested in rivals even if you aren't interested in Viatris stock.
47.06% Upside
Viatris Fair Value Forecast for 2023 - 2025 - 2030
In the last two years, Viatris's Price has fallen from $19.09 to $15.98 – a 16.29% decrease. According to 8 prominent analysts, Viatris's Fair Value will fall by 7.03% in the next year, reaching $14.86. Over the next eight years, experts predict that Viatris's Fair Value will grow at a rate of 12.16%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| JNJ Stock Forecast | Johnson & Johnson | Outperform |
10
|
$154.37 | Buy/Sell | $178.79 | 16.93% |
| LLY Stock Forecast | Eli Lilly & Co | Outperform |
14
|
$427.51 | Buy/Sell | $333.19 | -6.43% |
| ABBV Stock Forecast | AbbVie | Outperform |
10
|
$136.46 | Buy/Sell | $162.24 | 20.91% |
| PFE Stock Forecast | Pfizer Inc | Outperform |
3
|
$37.01 | Buy/Sell | $47.96 | 42.26% |
| MRK Stock Forecast | Merck | Outperform |
5
|
$109.18 | Buy/Sell | $99.57 | 8.08% |
Viatris Revenue Forecast for 2023 - 2025 - 2030
In the last two years, Viatris's Revenue has grown by 55.53%, rising from $11.50B to $17.89B. According to 6 prominent analysts, Viatris's Revenue will fall by 7.01% in the next year, reaching $16.63B. By 2030, professionals believe that Viatris's Revenue will decrease by 4.39%, reaching $17.10B – a concerning trend for the company.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| AZN Stock Forecast | AstraZeneca PLC | Buy |
8
|
£11.50k | Buy/Sell | £153.20 | -98.64% |
| NOVN Stock Forecast | Novartis | Hold |
10
|
CHF85.77 | Buy/Sell | CHF103.75 | 9.89% |
| BMY Stock Forecast | Bristol-Myers Squibb Co | Outperform |
2
|
$63.71 | Buy/Sell | $80.99 | 30.28% |
.jpg)
Viatris Dividend per Share Forecast for 2023 - 2025 - 2030
Viatris's Dividend per Share has decreased In the last zero years, from $0.45 to $0.45 – a 0.00% drop. For next year, analysts predict Dividend per Share of $0.51, which would mean an increase of 13.33%. In 2030, professionals predict that Viatris's Dividend per Share will decrease by 100.00%, to $0.00.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| AMGN Stock Forecast | Amgen Inc | Hold |
7
|
$218.56 | Buy/Sell | $268.00 | 27.20% |
| GILD Stock Forecast | Gilead Sciences Inc | Outperform |
11
|
$76.34 | Buy/Sell | $87.30 | 15.27% |
| REGN Stock Forecast | Regeneron Pharmaceuticals Inc | Outperform |
2
|
$728.60 | Buy/Sell | $796.73 | 7.33% |
Viatris Free Cash Flow Forecast for 2023 - 2025 - 2030
Viatris's Free Cash Flow has grown In the last two years, rising from $1.59B to $2.56B – a growth of 60.94%. In the next year, analysts believe that Free Cash Flow will reach $3.62B – an increase of 41.35%. For the next eight years, experts predict that Viatris's Free Cash Flow will grow at a rate of 61.12%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| GSK Stock Forecast | GSK | Outperform |
16
|
£1.37k | Buy/Sell | £16.95 | -98.83% |
| 4568 Stock Forecast | Daiichi Sankyo Company | Outperform |
18
|
¥4.07k | Buy/Sell | ¥0.00 | 35.30% |
| BAYN Stock Forecast | Bayer | Outperform |
7
|
53.42€ | Buy/Sell | 74.54€ | 41.33% |
Viatris Net Income Forecast for 2023 - 2025 - 2030
In the last two years, Viatris's Net Income has seen a drop from $16.80M to $-1.27B – a 7654.17% decrease. According to 6 major analysts, Viatris's Net Income will fall by 427.08% in the next year, reaching $4.15B. Professionals believe that By 2030, Viatris's Net Income will fall to $5.08B– a 500.13% decrease from its current value.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| RKT Stock Forecast | Reckitt Benckiser Group | Outperform |
16
|
£6.29k | Buy/Sell | £68.33 | -98.93% |
| BIIB Stock Forecast | Biogen Inc | Outperform |
11
|
$298.69 | Buy/Sell | $322.44 | 8.81% |
| ALC Stock Forecast | Alcon | Outperform |
15
|
CHF66.18 | Buy/Sell | CHF0.00 | 30.51% |
Viatris EBITDA Forecast for 2023 - 2025 - 2030
Viatris's EBITDA has seen impressive growth In the last two years, rising from $3.26B to $6.18B – a growth of 89.55%. According to 6 analysts, Viatris's EBITDA will fall by 3.11% in the next year, reaching $5.99B. For the next eight years, the forecast is for EBITDA to grow by 16.31%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| HZNP Stock Forecast | Horizon Therapeutics Public | Buy |
16
|
$113.00 | Buy/Sell | $0.00 | 23.89% |
| 4503 Stock Forecast | Astellas Pharma | Outperform |
18
|
¥1.92k | Buy/Sell | ¥0.00 | 24.74% |
| BAX Stock Forecast | Baxter International Inc | Outperform |
17
|
$40.33 | Buy/Sell | $60.73 | 43.81% |
Viatris EBIT Forecast for 2023 - 2025 - 2030
In the last two years, Viatris's EBIT has grown by 108.66%, rising from $1.42B to $2.97B. For the next year, analysts predict that EBIT will reach $5.60B – an increase of 88.68%. Over the next eight years, experts believe that Viatris's EBIT will grow at a rate of 113.19%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| LH Stock Forecast | Laboratory Corp of America Hol... | Outperform |
11
|
$211.93 | Buy/Sell | $278.38 | 29.76% |
| FRE Stock Forecast | Fresenius SE & Co. KGaA | Outperform |
18
|
26.16€ | Buy/Sell | 35.23€ | 24.24% |
| DIVISLAB Stock Forecast | Divi's Laboratories | Hold |
18
|
Rp3.43k | Buy/Sell | Rp5.23k | 42.86% |
Viatris EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last two years, Viatris's EPS has fallen from $4.42 to $3.70 – a 16.29% decrease. According to 8 prominent analysts, Viatris's EPS will fall by 7.03% in the next year, reaching $3.44. Over the next eight years, experts predict that Viatris's EPS will grow at a rate of 12.16%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CIPLA Stock Forecast | Cipla | Outperform |
18
|
Rp1.08k | Buy/Sell | Rp1.05k | 1.08% |
| JAZZ Stock Forecast | Jazz Pharmaceuticals | Outperform |
14
|
$158.79 | Buy/Sell | $0.00 | 25.95% |
| CTLT Stock Forecast | Catalent | Outperform |
15
|
$36.40 | Buy/Sell | $83.92 | 100.55% |
.jpg)